Comparison of the efficacy of Gd-EOB-DTPA-enhanced magnetic resonance imaging and magnetic resonance elastography in the detection and staging of hepatic fibrosis

Wen-Pei Wu, MD<sup>a,b</sup>, Cheng-In Hoi, BSc<sup>c</sup>, Ran-Chou Chen, MD<sup>d</sup>, Ching-Po Lin, PhD<sup>d</sup>, Chen-Te Chou, MD, PhD<sup>a,b,*</sup>

Abstract
The present study compared the efficacy of gadolinium ethoxybenzyl diethylene triamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and magnetic resonance elastography (MRE) in the estimation of hepatic fibrosis stages with histopathologic correlation.

This retrospective study included 104 patients (87 men and 17 women; mean age, 60.6 ± 10.6 years) with chronic liver disease who underwent both Gd-EOB-DTPA-enhanced MRI and MRE. The relative enhancement (RE) ratio of the liver parenchyma and the contrast enhancement index (CEI) were calculated as \( \frac{S_{\text{post}} - S_{\text{pre}}}{S_{\text{pre}}} \) and \( \frac{C_{\text{post}}}{C_{\text{pre}}} \), respectively, where \( S_{\text{post}} \) and \( S_{\text{pre}} \) were the liver-to-muscle signal intensity ratios on the hepatobiliary phase images and noncontrast-enhanced images, respectively. The liver stiffness values were measured using MRE stiffness maps. The diagnostic performance of MRE, RE ratios, and CEI values for hepatic fibrosis staging were compared.

The distribution of fibrosis stages was as follows: F0, n = 3 (2.9%); F1, n = 12 (11.5%); F2, n = 17 (16.3%); F3, n = 26 (25.0%); and F4, n = 46 (44.2%). MRE, RE ratios, and CEI values correlated significantly with hepatic fibrosis \( r_c = .79, .35, .25 \), respectively, \( P < .05 \). MRE showed a significantly higher diagnostic performance than did RE ratios and CEI values for each fibrosis stage, except while distinguishing the F1 fibrosis stage \( CEI, P = .15 \). A cutoff value of RE ratio = 0.89 can be used to identify patients with significant hepatic fibrosis, with positive predictive value, sensitivity, specificity, and negative predictive value of 93.2%, 61.8%, 73.3%, and 24.4%, respectively.

Gd-EOB-DTPA-enhanced MRI can potentially predict significant hepatic fibrosis. However, the diagnostic performance of MRE for hepatic fibrosis staging was superior to that of Gd-EOB-DTPA-enhanced MRI.

Abbreviations: Az = area under the ROC curve, CEI = contrast enhancement index, Gd-EOB-DTPA = gadolinium ethoxybenzyl diethylene triamine pentaacetic acid, MRE = magnetic resonance elastography, NPV = negative predictive value, PPV = positive predictive value, RE = relative enhancement, ROC = receiver operating characteristic, ROI = region of interest.

Keywords: cirrhosis, Gd-EOB-DTPA-enhanced MRI, hepatic fibrosis, magnetic resonance elastography

1. Introduction
Hepatic fibrosis is the accumulation of extracellular matrix proteins in response to acute or chronic liver diseases.\(^{1,2}\) Hepatitis B and hepatitis C, which are major causes of chronic liver diseases, such as liver cirrhosis and hepatocellular carcinoma, are highly prevalent in Taiwan.\(^{13-5}\) The complications of liver cirrhosis and hepatocellular carcinoma are among the 10 leading causes of death in Taiwan annually. Therefore, hepatic fibrosis is very important for diagnosis in clinical situations. Liver biopsy is the gold standard for fibrosis staging in clinical diagnosis. However, it is invasive and is not preferred by patients. Furthermore, it lacks repeatability for tracing patient’s status after treatment. In addition, only some of the local liver parenchymal tissues are extracted for pathological analysis; therefore, liver biopsy cannot predict the fibrosis severity of whole liver. Thus, a noninvasive and reliable method is required for fibrosis staging.\(^{6-8}\)

A hepatocyte-specific contrast agent, gadolinium ethoxybenzyl diethylene triamine pentaacetic acid (Gd-EOB-DTPA), has been widely used. It has been reported to enhance the detection and diagnosis of hepatocellular carcinoma and has been regarded as a functional contrast medium.\(^{9,10}\) Hepatocytes internalize Gd-EOB-DTPA, which allows the signal intensity (SI)-based measurement of the liver parenchyma for quantitative assessment of liver functions.\(^{11-13}\) It may be a potential one-step method for evaluating the liver functions and liver tumor characteristics. Previous studies showed that patients with liver dysfunction presented with reduction of liver parenchymal enhancement by the quantitative methods of direct measurement of liver...
parenchyma signal intensity. However, it was still uncertain whether the severity of hepatic fibrosis would correlate with the impaired uptake of Gd-EOB-DTPA and in turn the reduced liver parenchymal enhancement due to the damaged severity of hepatocyte function and the decreased number of hepatocytes.

Magnetic resonance elastography (MRE) is a newly developed noninvasive method to predict the stages of hepatic fibrosis, to identify the esophageal varices in patients with liver cirrhosis, and for prognosis of patients with acute liver injury. To date, liver stiffness measurements obtained through MRE have been reported to accurately predict hepatic fibrosis in patients with chronic hepatitis. However, MRE requires active and passive drivers and is not widely used as yet.

Therefore, the present study compared the diagnostic performances of Gd-EOB-DTPA-enhanced MRI and MRE in hepatic fibrosis staging.

2. Materials and methods

2.1. Patients

This retrospective study was approved by the institutional review board. The following patients were included in the study: patients with chronic liver disease who received histopathological confirmation for predicting the different stages of hepatic fibrosis and those who underwent Gd-EOB-DTPA-enhanced MRI and MRE within 6 months before histological confirmation. From February 2012 to December 2014, a total of 104 patients (87 men and 17 women; mean age, 60.6 ± 10.6 years; body mass index, 24.5 ± 3.3 kg/m²) were included in the present study.

2.2. Magnetic resonance imaging

All MRI examinations of the liver were performed using a 1.5-T MRI scanner (Avanto, Siemens Healthcare, Erlangen, Germany) with a 16-channel phased-array body coil for obtaining routine Gd-EOB-DTPA-enhanced MRI and MRE images. All patients were fasted for at least 4 hours before MRI examinations. For Gd-EOB-DTPA-enhanced MRI, all patients received a 0.025 mmol/kg (0.1 mL/kg) peripheral IV bolus of Gd-EOB-DTPA (Primovist, Bayer Schering Pharma, Berlin, Germany) at a speed of approximately 2 mL/s. The line was flushed with 20 mL of 0.9% saline. MRI examinations were performed using dynamic T1-weighted (T1-W) fat-saturated 3-dimensional volumetric interpolated breath-holding sequences (repetition time [TR]/echo time[TE], 3.7 ms/1.4 ms; flip angle, 10°; slice thickness, 3 mm; matrix, 512 x 400; number of excitations, 1) before and 2.5 to 30 seconds (arterial phase), 55 to 60 seconds (portal phase), 85 to 90 seconds (venous phase), and 20 minutes (hepatobiliary phase) after the injection of Gd-EOB-DTPA.

2.3. Magnetic resonance elastography

MRE was performed after Gd-EOB-DTPA-enhanced MRI. MRE was performed with the patient in a supine position using a cylindrical pneumatic passive driver (diameter, 19 cm; thickness, 1.5 cm; Rochester, MN). The passive driver was placed over the right lower chest and anterior abdominal wall of the patient with the center of the driver at the xiphisternum level. The active driver generated continuous low-amplitude mechanical vibrations of 60 Hz. The active and passive drivers were connected by a 7.6-cm long plastic tube. Mechanical waves were transmitted into the liver by the passive driver. The parameters of the MRE sequence were as follows: TR/TE, 50 milliseconds/22.7 milliseconds; flip angle, 25°; bandwidth, 260 Hz/pixel; imaging frequency, 63.5 MHz; matrix, 256 x 256; slice thickness, 7 mm; field of view, 400 x 400 mm². The scanning time of each axial slice was 21 seconds per breath-hold. A total of 5 slices were acquired for each MRE examination. All postprocessing steps were performed automatically, and the liver stiffness values were presented in kilopascal. The MRE software also generated a confidence map, automatically demonstrating the regions with adequate wave amplitude.

2.4. Liver stiffness measurement

All analyses were performed on a dual-screen diagnostic workstation (GE Healthcare, Milwaukee, WI). Two readers (WPW and CIH, with 8 and 2 years of experience in interpreting liver MR images, respectively) individually analyzed the MRE measurements. The readers were blinded to patients' clinical data and histopathologic results. To determine the intraclass reliability, 1 reader (CIH) obtained all quantitative MRE measurements 2 times with the time interval of 6 months. For measuring the liver stiffness, the wave images were first evaluated for adequate wave quality. On each axial image of the confidence map, a region of interest (ROI) was manually drawn to include only the liver parenchyma (Fig. 1). The areas on the confidence map that were considered invalid were excluded. In addition, we attempted to avoid artifacts, such as wave interference, liver edges, major blood vessels, and hepatic tumors. The mean liver stiffness values for each MR elastogram were recorded. The stiffness values of the liver parenchyma were calculated by averaging the mean liver stiffness values of the 5 slices in each patient.

2.5. Gd-EOB-DTPA-enhanced MRI

The Gd-EOB-DTPA-enhanced MRI SIs were measured on the same workstation 2 times with the time interval of 6 months to determine the intraclass reliability. On the precontrast T1-W images and the Gd-EOB-DTPA-enhanced hepatobiliary phase images, circular ROIs were drawn on the anterior lobe of the liver and paraspinous muscle on the same axial image as large as possible, excluding the major blood vessels, hepatic tumors, liver edges, and artifacts (Fig. 1). Identical ROIs were placed on the images before and after the administration of Gd-EOB-DTPA. Quantitative liver enhancement measurements included the relative enhancement (RE) ratio and the contrast enhancement index (CEI). RE ratios of the liver were calculated using the precontrast and postcontrast hepatobiliary phase SI measurements of the liver parenchyma as follows: SImost/SImost liver)/SIcontrast.[23] The CEI values were calculated as SImost/SIcontrast and the liver-to-muscle SI ratio was calculated separately as a ratio of the SI of the liver parenchyma to that of the paraspinous muscle on the noncontrast-enhanced images (SIcontrast) and on the hepatobiliary phase images (SIcontrast).[24]

2.6. Histopathological analysis

Hepatic fibrosis was diagnosed based on the histopathological analysis of the percutaneous liver biopsy specimens (n = 28) or surgical resection specimens (n = 76). Liver biopsies were performed using an 18-gauge cutting needle biopsy under sonography or computed tomography guiding. The location of biopsy was in left lobe (n = 6) or in right lobe (n = 21). Tissue samples were fixed in buffered formalin and embedded in...
All specimens were stained with hematoxylin and eosin stain and Masson trichrome stain and were analyzed by an experienced attending hepatopathologist who was blinded to the clinical, biochemical, and MR examination results. All liver samples with specimen size ≥10 mm and portal tracts ≥5 were considered adequate. Hepatic fibrosis was staged on a scale of F0 to F4 according to the METAVIR scoring system (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with few septa; F3: numerous septa without cirrhosis; F4: cirrhosis).

2.7. Statistical analyses

Statistical analyses were performed using Statistical Package for the Social Sciences (version 20.0 for Windows; Chicago, IL) and MedCalc Programme (MedCalc Software, Mariakerke, Belgium). Spearman correlation analysis was performed to evaluate the relationship between hepatic fibrosis stages, RE ratio, CEI values, and liver stiffness values measured through MRE. To investigate the interobserver reliability and intra-observer reliability, absolute agreement intraclass correlation coefficients were calculated for both MRE, RE ratios, and CEI ratios. The diagnostic performances of RE ratios, CEI values, and MRE were determined through receiver operating characteristic (ROC) analysis. In addition, the sensitivity, specificity, area under the ROC curve (Az), positive predictive value (PPV), negative predictive value (NPV), and accuracy of RE ratios, CEI values, and MRE were demonstrated. The MedCalc ROC curve module was used to compare the significant differences between the Azs for RE ratio, CEI, and MRE. P < .05 was considered statistically significant.

3. Results

3.1. Baseline characteristics of the study patients

Table 1 presents the baseline clinical characteristics of the study patients. The distribution of fibrosis stages among the 104 patients were as follows: F0, n = 3 (2.9%); F1, n = 12 (11.5%); F2, n = 17 (16.3%); F3, n = 26 (25.0%); and F4, n = 46 (44.2%). No adverse events occurred among these studies.

| Number of patients | 104 |
|--------------------|-----|
| Gender (male/female)| 87/17 |
| Age (mean ± SD)     | 60.6 ± 10.6 |
| BMI, kg/cm²         | 24.5 ± 3.5 |
| Chronic liver disease |
| HBV                | 54 |
| HCV                | 32 |
| HBV+HCV            | 1 |
| Alcoholic liver disease | 6 |
| Unknown            | 11 |
| METAVIR scoring system |
| F0                 | 3 |
| F1                 | 12 |
| F2                 | 17 |
| F3                 | 26 |
| F4                 | 46 |

BMI = body mass index, HBV = hepatitis B virus, HCV = hepatitis C virus, SD = standard deviation. Unknown liver diseases may be caused by nonalcoholic steatohepatitis, autoimmune hepatitis, and cryptogenic hepatitis.
3.2. Diagnostic performance of MRE, RE Ratios, and CEI values in predicting hepatic fibrosis stages

The mean liver stiffness values measured through MRE increased as the hepatic fibrosis stages progressed (rs = 0.79, P < .001; Fig. 2C). The interobserver reliability between MRE-reader 1 and MRE-reader 2 was 0.98, P < .001. The intraobserver reliability of MRE was 0.95, indicating excellent reliability. MRE-measured liver stiffness values differed significantly between all stages of liver fibrosis (P < .05). The optimal cutoff values of liver stiffness were 2.68 kPa for ≥F1 (F0 vs F1-F4; sensitivity, 92.1%; specificity, 100%), 3.23 kPa for ≥F2 (F0-F1 vs F2-F4; sensitivity, 86.5%; specificity, 93.3%), 3.56 kPa for ≥F3 (F0-F2 vs F3-F4; sensitivity, 83.3%; specificity, 90.6%), and 4.02 kPa for F4 (F0-F3 vs F4; sensitivity, 82.6%; specificity, 81.0%).

Negative correlations were observed between the RE ratios, CEI values, and the hepatic fibrosis stages independently (RE ratio, r = -0.35, P < .001; CEI, r = -0.25, P = .01), indicating that as the hepatic fibrosis stages progressed, the RE ratios and CEI values decreased (Fig. 2A and B). The interobserver and intraobserver reliability for RE and CEI was 0.85 and 0.84, 0.90 and 0.82, respectively, and the RE ratios and CEI measured values had excellent reliability. RE differed significantly between all stages of fibrosis with the exception of F0 and F1 (P = .63). The cutoff values of RE ratio were 1.12 for ≥F1 (sensitivity, 91.1%; specificity, 33.3%), 0.89 for ≥F2 (sensitivity, 61.8%; specificity, 73.3%), 0.81 for ≥F3 (sensitivity, 58.3%; specificity, 84.4%), and 0.79 for F4 (sensitivity, 63.0%; specificity, 72.4%). CEI differed significantly only between F1 and F2 (P = .03), and between F2 and F3 (P = .004). The cutoff values of CEI were 1.75 for ≥F1 (sensitivity, 74.3%; specificity, 66.7%), 1.57 for ≥F2 (sensitivity, 49.4%; specificity, 80.0%), 1.55 for ≥F3 (sensitivity, 52.8%; specificity, 81.3%), and 1.51 for F4 (sensitivity, 39.1%; specificity, 70.7%; Table 2, Fig. 3).

The diagnostic performances of MRE, RE ratios, and CEI values at corresponding METAVIR hepatic fibrosis stages were compared; RE ratios had a slightly higher AUC than did CEI values, except when distinguishing the F1 fibrosis stage. However, the differences were not significant (P = .29, .84, .26, and .10 for ≥F1, F2, F3, and F4, respectively; not shown in Table 2).

As shown in Table 2, MRE had an excellent and significantly superior diagnostic ability than that of RE ratio and CEI in predicting each METAVIR hepatic fibrosis stage, except when predicting F0 versus F1 to F4 (CEI, P = .15).

4. Discussion

Gd-EOB-DTPA is a gadolinium-based contrast agent, which is mediated by a functional hepatocyte through an active transport system that involves factors such as the organic anion-transporting polypeptide. The intracellular uptake of Gd-EOB-DTPA may decrease because of impaired liver
functions. Therefore, SI measurements of the liver parenchyma in the hepatobiliary phase after the administration of a peripheral IV bolus of Gd-EOB-DTPA could be a direct quantitative method for assessing the degree of hepatocellular functions. Moreover, Gd-EOB-DTPA-enhanced MRI is based on a routine clinical imaging protocol and could provide additional information in addition to accurate diagnosis of focal hepatic lesions.

### Table 2

| Cutoff | Az (95% CI) | Sn | Sp | PPV | NPV | Accuracy | P |
|--------|-------------|----|----|-----|-----|----------|---|
| RE     |             |    |    |     |     |          |   |
| ≥F1    | <1.12       | 0.569 (0.469–0.666) | 91.1% | 33.3% | 97.9% | 10.0% | 89.4% | .04 |
| ≥F2    | <0.89       | 0.672 (0.573–0.761) | 61.8% | 73.3% | 93.2% | 24.4% | 63.5% | .002 |
| ≥F3    | <0.81       | 0.725 (0.628–0.808) | 58.3% | 84.4% | 89.4% | 47.4% | 66.4% | <.001 |
| ≥F4    | <0.79       | 0.666 (0.567–0.756) | 63.0% | 72.4% | 64.4% | 71.2% | 68.3% | <.001 |
| CEI    |             |    |    |     |     |          |   |
| ≥F1    | ≤1.75       | 0.634 (0.534–0.736) | 74.3% | 66.7% | 98.7% | 7.1%  | 74.0% | .15 |
| ≥F2    | ≤1.57       | 0.661 (0.562–0.751) | 49.4% | 80.0% | 93.6% | 21.1% | 53.9% | .002 |
| ≥F3    | ≤1.55       | 0.673 (0.574–0.762) | 52.8% | 81.3% | 86.4% | 43.3% | 61.5% | <.001 |
| ≥F4    | ≤1.51       | 0.602 (0.501–0.696) | 39.1% | 70.7% | 52.9% | 60.0% | 57.7% | <.001 |
| MRE, kPa |           |    |    |     |     |          |   |
| ≥F1    | ≥2.68       | 0.955 (0.896–0.986) | 92.1% | 100.0% | 100.0% | 27.3% | 92.3% | .15 |
| ≥F2    | ≥3.23       | 0.933 (0.867–0.973) | 86.5% | 93.3% | 98.7% | 53.9% | 87.5% | .002 |
| ≥F3    | ≥3.55       | 0.935 (0.869–0.974) | 83.3% | 90.6% | 95.2% | 70.7% | 85.6% | .001 |
| ≥F4    | ≥4.02       | 0.909 (0.836–0.956) | 82.6% | 81.0% | 77.6% | 85.5% | 81.7% | <.001 |

Az = area under the curve, CEI = contrast enhancement index, kPa = kilopascal, MRE = magnetic resonance elastography, NPV = negative predictive value, PPV = positive predictive value, RE = relative enhancement, Sn = sensitivity, Sp = specificity.

Accuracy represents the ratios of patients who were classified appropriately (true positive + true negative).

P value represents the comparison between the area under the curve of RE ratio and CEI with that of MRE at each corresponding fibrosis stage.

---

**Figure 3.** Receiver operating characteristic (ROC) curve analysis for F ≥1 (A), F ≥2 (B), F ≥3 (C), F ≥4 (D) of magnetic resonance elastography (MRE), relative enhancement ratio (RE), and contrast enhancement index (CEI) of liver parenchyma on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) images.
Comparison of quantitative methods on Gd-EOB-DTPA-enhanced MR images to staging hepatic fibrosis in the literature review.

| Author         | Year | Journal       | N     | Disease (n)                  | Fibrosis (n) | Tesla | Quantitative methods | Correlation | AUC   | Cutoff | Sn, % | Sp, % |
|----------------|------|---------------|-------|------------------------------|--------------|-------|----------------------|-------------|-------|--------|-------|-------|
| Watanabe et al | 2011 | Radiology     | 114   | Chronic Liver disease of focal liver (99) | F0 (18)      | 3     | CEI                  | −0.79       | −0.56 |
|                |      |               |       | None (15)                    | F1 (20)      |       | Post-liver SI ratio  |             |       |
|                |      |               |       |                               | F2 (15)      |       |                      |             |       |
|                |      |               |       |                               | F3 (31)      |       |                      |             |       |
|                |      |               |       |                               | F4 (30)      |       |                      |             |       |
| Motosugi et al | 2011 | Magn Res Imaging | 100  | HCV (45) HBV (17) Alcoholism (2) Others (20) None (16) | F0 (16)      | 1.5   | Liver-spleen contrast ratio | −0.393      | 0.68  | 1.76   | 74.6  | 56.0  |
|                |      |               |       |                               | F1 (17)      |       | Corrected liver enhancement ratio | −0.322      |       |
|                |      |               |       |                               | F2 (10)      |       | Spleen index         | −0.331      |       |
| Choi et al     | 2013 | Invest Radiol | 168   | HBV (120) Alcoholism (6) Others (17) | F0 (23)      | 1.5   | CEI                  | −0.378      | 0.622 | 1.609  | 46.3  | 82.4  |
|                |      |               |       | None (16)                    | F1 (14)      |       |                      |             |       |
|                |      |               |       |                               | F2 (32)      |       |                      |             |       |
|                |      |               |       |                               | F3 (39)      |       |                      |             |       |
|                |      |               |       |                               | F4 (65)      |       |                      |             |       |
| Feier et al    | 2013 | Radiology     | 102   | HCV (38) HBV (21) Autoimmune hepatitis (14) | F0 (23)      | 3     | RE                   | −0.65       | 0.82  | 1.18   | 75    | 77    |
|                |      |               |       |                               | F1 (11)      |       |                      |             |       |
|                |      |               |       |                               | F2 (14)      |       |                      |             |       |
|                |      |               |       |                               | F3 (13)      |       |                      |             |       |
|                |      |               |       |                               | F4 (41)      |       |                      |             |       |
| Jang et al     | 2013 | Ann Hepatol   | 113   | HBV (82) HCV (9) Alcoholism (5) None (17) | F0 (13)      | 3     | CEI                  | −0.545      | 0.703 | 1.32   | 50    | 93.5  |
|                |      |               |       |                               | F1 (18)      |       |                      |             |       |
|                |      |               |       |                               | F2 (15)      |       |                      |             |       |
|                |      |               |       |                               | F3 (32)      |       |                      |             |       |
|                |      |               |       |                               | F4 (36)      |       |                      |             |       |
| Nojiri et al   | 2013 | J Gastroenterol| 224  | HCV (224) | F0 (26) | 1.5 | RE                   | −0.478      | 0.83  | 1.38   | 50.9  | 97.4  |
|                |      | Hepatol       |       |                               | F1 (39)      |       | Liver-to-intervertebral disk ratio | −0.661      | 0.88  |
|                |      |               |       |                               | F2 (31)      |       | s                    | −0.463      | 0.83  |
|                |      |               |       |                               | F3 (66)      |       | s                    | −0.376      | 0.77  |
|                |      |               |       |                               | F4 (62)      |       | s                    |             |       |
| Park et al     | 2014 | World J Gastroenterol | 42   | HCV (16) HBV (4) NAFLD (3) None (19) | F0 (23)      | 3     | CEI                  | −0.321      |       |
|                |      |               |       |                               | F1 (17)      |       |                      |             |       |
|                |      |               |       |                               | F2 (17)      |       |                      |             |       |
|                |      |               |       |                               | F3 (25)      |       |                      |             |       |
| Wu et al       | Present | Medicine (2017) | 104  | HBV (54) HBV+HCV (1) Alcoholism (6) Unknown (11) | F0 (3)       | 1.5   | RE                   | −0.345      | 0.672 | 0.89   | 61.8  | 73.3  |
|                |      |               |       |                               | F1 (17)      |       | CEI                  | −0.246      | 0.661 | 1.57   | 49.4  | 80.0  |

AUC = area under the receiver operating characteristic curve, CEI = contrast enhancement index, HBV = hepatitis B virus, HCV = hepatitis C virus, NAFLD = nonalcoholic fatty liver disease, RE = relative enhancement, Sn = sensitivity, Sp = specificity.

In our study, the RE ratio ($r_c = -0.35; P < .001$) and CEI ($r_c = -0.25; P = .01$) exhibited mild negative correlations with the hepatic fibrosis stages, indicating that as the hepatic fibrosis stages progress, the patients’ RE ratios and CEI values might decrease. Quantitative analysis of the liver parenchyma revealed that the Az of the RE ratio at each fibrosis stage was slightly higher than that of CEI, except at the F1 stage; however, the differences were not significant. The diagnostic performance of different quantitative methods on Gd-EOB-DTPA MR images varied as the correlation ranged from $-0.32$ to $-0.79$ (Table 3). Our results are consistent with previous studies. In contrast, Watanabe et al. and Feier et al. revealed a moderately strong correlation between Gd-EOB-DTPA-enhanced MRI and hepatic fibrosis stages. This inconsistency in the findings may be due to relatively fewer patients with F0 hepatic fibrosis being enrolled in our study, which might affect the statistical results. However, in clinical practice, patients who undergo Gd-EOB-DTPA-enhanced MRI imaging for focal liver lesions often have chronic liver disease. In addition, differences between the MRI scanners may affect the results; a higher contrast-to-noise ratio of gadolinium chelate-based contrast agents can be achieved with a 3.0-T MRI scanner than with a 1.5-T MRI scanner. Therefore, the differences in the SIs of the liver parenchyma before and after Gd-EOB-DTPA injection may be more pronounced with a 3.0-T MRI scanner than with a 1.5-T MRI scanner.

Our results revealed that RE ratios and CEI values have acceptable PPV (93.2–98.7%) for distinguishing between mild and significant fibrosis and a low NPV (7.1–24.4%). For quantitative assessment of the contrast enhancement in liver parenchyma, Gd-EOB-DTPA-enhanced MRI might be a possible method for predicting significant hepatic fibrosis using the cutoff...
values of 0.89 and 1.57 for RE ratio and CEI, respectively. Therefore, Gd-EOB-DTPA-enhanced MRI of the liver might be a potential one-step method for evaluating hepatic fibrosis stages and the characteristics of the focal liver lesions. Recently, optimal personalized treatments have been developed to reduce the risk of chronic liver disease-associated complications. Patients with significant fibrosis have benefited by initiating antiviral therapy according to the latest American Association for the Society of Liver Disease and European Association for the Study of Liver treatment guidelines.[26–29] Although noninvasive diagnostic imaging has been used as an initial test for risk stratification of hepatic fibrosis (National Institute for Health and Care Excellence),[30] Gd-EOB-DTPA-enhanced MRI cannot replace liver biopsy because of low sensitivity and NPV.

The liver stiffness values measured through MRE (r=0.79) had a strong correlation with hepatic fibrosis stages. Our results indicated that diagnostic performance of MRE is significantly higher than that of RE ratios and CEI values, which may be because the liver stiffness values are related to the pathological changes that occur in the liver structure during hepatic fibrosis. By contrast, RE ratios and CEI values are associated with hepatocellular functions. Moreover, a patient with significant fibrosis or liver cirrhosis may have satisfactory liver functions.

In our study, the liver stiffness values measured through MRE not only showed a substantial correlation with the hepatic fibrosis stages but also effectively predicted the hepatic fibrosis stages. MRE predicted significant fibrosis (≥F2) with high sensitivity (86.5%) and specificity (93.3%). Therefore, MRE can possibly predict significant fibrosis and provide early clinical diagnosis.[27,31]

The present study had several limitations. First, this study had a retrospective design; therefore, the relatively small number of patients might undermine the reliability. Second, the hepatic fibrosis stages were not equally distributed in our study population; only a few patients with F0 fibrosis were included, which may have affected the statistical results. Moreover, only patients with chronic liver disease who underwent both Gd-EOB-DTPA-enhanced MRI and MRE were included, which might explain the low prevalence of early fibrosis in our study population. Therefore, additional prospective investigations with a larger study population are warranted.

In conclusion, the diagnostic performance of MRE for hepatic fibrosis staging is superior to that of Gd-EOB-DTPA-enhanced MRI. RE ratios and CEI values exhibited a mild correlation with the hepatic fibrosis stages. MRE is a promising noninvasive tool for hepatic fibrosis staging.

References
[1] Akolado R, Arthur MJ, Irdade JP. Pathogenesis of liver fibrosis. Clin Sci 1997;92:103–12.
[2] Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–71.
[3] Merican I, Guan R, Amapatuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1536–61.
[4] Kao JH. Hepatitis C virus infection in Taiwan: past, present, and future. J Formos Med Assoc 2016;115:65–6.
[5] Chang IC, Huang SF, Chen PJ, et al. The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan Liver Cancer Network. Medicine (Baltimore) 2016;95:e3284.
[6] Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57.
[7] Yoon JH, Lee JM, Woo HS, et al. Staging of hepatic fibrosis: comparison of magnetic resonance elastography and shear wave elastography in the same individuals. Korean J Radiol 2013;14:202–12.
[8] The French METAVIR Cooperative Study GroupIntraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20(part 1):115–20.
[9] Bormann RL, da Rocha EL, Kiezenbaum ML, et al. The role of gadodetic acid as a paramagnetic contrast medium in the characterization and detection of focal liver lesions: a review. Radiol Bras 2013;48:43–51.
[10] Fayad LM, Kamel IR, Mitchell DG, et al. Functional MR cholangiography: diagnosis of functional abnormalities of the gallbladder and biliary tree. AJR Am J Roentgenol 2005;184:1563–71.
[11] Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009;30:1042–6.
[12] Nojin S, Kusakabe A, Fujiwara K, et al. Noninvasive evaluation of hepatic fibrosis in hepatitis C virus-infected patients using ethoxybenzyl-magnetic resonance imaging. J Gastroenterol Hepatol 2013;28:1032–9.
[13] Zhao X, Huang M, Zha Q, et al. The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magn Reson Imaging 2015;33:768–73.
[14] Jang YJ, Cho SH, Bae JH, et al. Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI. Ann Hepatol 2013;12:926–34.
[15] Motosugi U, Ichikawa T, Oguni M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011;29:1047–52.
[16] Tamada T, Ito K, Higaki A, et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. J Radiol 2011;00:311–6.
[17] Watanabe H, Katamura M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging: preliminary observations. Radiology 2011;259:142–50.
[18] Kanki A, Tamada T, Higaki A, et al. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012;30:536–60.
[19] Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015;13:440.e6–51.e6.
[20] Venkatesh SK, Wang G, Lim SG, et al. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol 2014;24:70–8.
[21] Sun HY, Lee JM, Han JK, et al. Usefulness of MR elastography for predicting esophageal varices in cirrhotic patients. J Magn Reson Imaging 2014;39:559–66.
[22] Kuroda H, Kakassa K, Obawa T, et al. Liver stiffness measured by acoustic radiation force impulse elastography reflects the severity of liver damage and prognosis in patients with acute liver failure. Hepatol Res 2014;45:571–7.
[23] Reier D, Balassy C, Bastani N, et al. Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology 2013;269:460–8.
[24] Choi YR, Lee JM, Yoon JH, et al. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic resonance imaging for the evaluation of hepatic fibrosis. Invest Radiol 2013;48:607–13.
[25] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The META VIR Cooperative Study Group. Hepatology 1996;24:289–93.
[26] European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.
[27] European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis C virus infection. J Hepatol 2014;60:392–420.
[28] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–2.
[29] Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014;20:6262–78.
[30] Sarri G, Westby M, Berrington S, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 2013;346:f3893.
[31] Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–44.